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Antibodies to human leukocyte antigens (HLAs) are a risk
factor for acute renal allograft rejection and loss. The role of
non-HLAs and their significance to allograft rejection have
gained recent attention. Here, we applied protein microarray
technology, with the capacity to simultaneously identify 5056
potential antigen targets, to assess non-HLA antibody
formation in 15 pediatric renal transplant recipients during
allograft rejection. Comparison of the pre- and post-
transplant serum identified de novo antibodies to 229 non-
HLA targets, 36 of which were present in multiple patients at
allograft rejection. On the basis of its reactivity, protein
kinase Cf (PKCf) was selected for confirmatory testing and
clinical study. Immunohistochemical analysis found PKCf
both within the renal tissue and infiltrating lymphocytes at
rejection. Patients who had an elevated anti-PKCf titer
developed rejection, which was significantly more likely to
result in graft loss. The absence of C4d deposition in patients
with high anti-PKCf titers suggests that it is a marker of
severe allograft injury rather than itself being pathogenic.
Presumably, critical renal injury and inflammation associated
with this rejection subtype lead to the immunological
exposure of PKCf with resultant antibody formation.
Prospective assessment of serum anti-PKCf levels at allograft
rejection will be needed to confirm these results.
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Although advances in allograft allocation and immunosup-
pression have reduced the incidence of acute rejection (AR)
episodes after renal transplantation, AR remains a significant
risk factor for allograft failure.1,2 Donor-specific antibodies
(DSAs), are widely recognized as a risk factor, both for AR
and for allograft loss.3 Recently, antibodies to non-human
leukocyte antigens (non-HLAs) have been the subject of
more intense scrutiny. The Collaborative Transplant Study
described 4048 HLA-identical sibling transplants.4 In the
course of 10 posttransplant years, a higher panel-reactive
antibody was associated with significantly lower allograft
survival. As these transplants involved HLA-identical siblings,
the increase in allograft loss could not be attributed to DSAs.
This study did not specifically detect non-HLA antibodies
nor did it show causality, but it clearly established the
negative impact of ‘non-HLA immunity’ on allograft survival
and function. Collins et al.5 described C4d deposition in the
absence of DSAs in HLA-identical, ABO-compatible renal
allograft recipients who had experienced allograft failure.
Although they were unable to investigate or identify non-
HLA antibodies in these patients, the occurrence of presumed
antibody-mediated rejection in these HLA-identical patients
was thought to be caused by non-HLA alloantibody
production.
Thus far, only a few non-HLA antibodies have been
identified in humans.6–10 In addition, the absence of
commercially available, validated detection strategies has
hampered our ability to determine their clinical relevance
and ascertain whether these antibodies are truly patho-
genic.11,12 Protein microarrays offer a novel technique for the
identification of patient-specific serum antibodies to non-
HLA immunological targets, allowing simultaneous detection
of antibodies to thousands of potential antigens. Although
this technique has been applied to human autoimmune and
oncological disease, our study represents the first use in the
field of solid organ transplantation.13,14
We applied protein microarray technology to 15 pediatric
patients who had experienced AR after renal transplantation.
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By paired comparative analysis using both pre-transplant and
posttransplant serum samples,15 the protein microarray was
able to identify 36 de novo antibody targets that were present
in at least two patients at AR. In addition, a high antibody
titer to one of these targets, protein kinase C-z (PKCz), was
associated with a recalcitrant subtype of AR and a
significantly greater risk of allograft loss.
RESULTS
Antigen discovery using protein microarray
A total of 15 pediatric (mean age at transplantation 12.4±5.2
years) kidney transplant patients, with a mean HLA
mismatch score of 4.1, were examined in our antigen
discovery phase (Table 1). In total, 12 patients received
steroid-free maintenance immunosuppression consisting of
tacrolimus and mycophenolate mofetil, whereas the three
remaining patients received steroid-based maintenance im-
munosuppression consisting of tacrolimus, mycophenolate
mofetil, and prednisone. The patients developed AR at a
mean of 22.3±20.7 months posttransplant. All patients
experienced acute cellular rejection of whom four patients
had Banff 1a rejection, eight patients had Banff 1b rejection,
and three patients had Banff 2a rejection. Of the 15 patients
with cellular rejection, only 4 (27%) had additional evidence
of antibody-mediated rejection, based on positive C4d stain-
ing and the presence of DSAs. However, 53% (8/15) had at
least one DSA at AR, whereas an additional 27% (4/15) had
at least one non-DSA HLA antibody detected at AR.
At AR, de novo, serological, non-HLA responses were
detected against 4.5% of the protein microarray targets (229/
5056). At least one target was recognized in all patients, 36
targets were identified in at least two patients at AR. The
mean protein microarray delta signal intensity of these targets
in their respective patients was 1390±1061 intensity units
compared with the mean delta signal intensity for all 5056
targets across all of the 15 patients, which was 7.6±198.3
(standard error, 0.7) intensity units. Patients with detectable
anti-HLA recognized a mean of 24.4±15.4 non-HLA antigen
targets. Patients without evidence of anti-HLA recognized a
mean of 79.3±108.9 non-HLA antigen targets. This
difference was not statistically significant (P¼ 0.47); the
greater mean number and larger standard deviation of non-
HLA antigen targets recognized in patients without anti-HLA
reactivity was primarily due to the fact that one of the three
patients in this group recognized substantially more non-
HLA antigens (205).
As this was a pilot study designed to assess the utility of
the protein microarray technique in pediatric renal transplant
recipients, we chose to focus our analysis on a single target,
PKCz, which had the highest mean signal intensity (6408
intensity units) of all 36 targets that were identified in two or
more patients. In addition to having the strongest mean
ProtoArray (Invitrogen, Carlsbad, CA, USA) signal, PKCz
was known to be expressed within renal parenchymal tissue,
and has been shown to be actively involved in regulation of
inflammation, cell survival, and apoptosis.16–24
Antigen validation of protein microarray results by
enzyme-linked immunosorbent assay
Protein kinase C-z was analyzed by enzyme-linked immu-
nosorbent assay (ELISA) across all 15 AR patients of the
study set; ELISA showed a significant positive correlation
with the protein microarray results (R2¼ 0.84, P-value
o0.001). Confirmation of ProtoArray-detected antibody
presence and signal intensity, to our knowledge, has been
validated for the first time in this study by ELISA. ELISA-
determined at-event serum anti-PKCz levels were plotted for
the pre-transplant and the at-AR samples for each of the 15
patients, as well as for the posttransplant samples of 28 stable
posttransplant patients who served as controls (Figure 1).
The clinical characteristics of these control patients were
similar to those of the 15 patients experiencing AR, with the
exception of event time posttransplant (Table 1). AR
occurred, on average, 22.3±20.7 months after transplant,
whereas the biopsy showing the absence of AR occurred, on
average, 6.6±3.4 months after transplant in the control
patients (Po0.005). The mean anti-PKCz serum levels for
the pre-transplant, at-AR, and posttransplant stable control
samples were 30.9±5.1 pg/ml, 46.7±34.9 pg/ml, and
34.8±8.6 pg/ml, respectively. Although there was a slight
trend toward higher anti-PKCz levels in the at-AR samples,
this failed to reach statistical significance (P¼ 0.07).
When the at-AR samples were further analyzed, the anti-
PKCz levels determined by ELISA were dramatically higher in
Table 1 | Patient demographics
Characteristic
Patients
with acute
rejection
Stable
posttransplant
patients P-value
Number of patients 15 28
Age at transplant (years) 12.4±5.2 13.4±5.7 0.6
HLA mismatch score 4.1±1.9 4.2±1.5 0.9
Gender 0.9
Male 67% 68%
Female 33% 32%
Allograft donor 0.4
Living donor 53% 39%
Deceased donor 47% 61%
Maintenance immunosuppression 0.7
Steroid free 80% 75%
Steroid based 20% 25%
Months posttransplant o0.005
At acute rejection 22.3±20.7
At stable biopsy 6.6±3.4
HLA, human leukocyte antigen.
Association of clinical variables between posttransplant patients who developed
acute allograft rejection and posttransplant patients who did not develop acute
allograft rejection. P-values o0.05 represent a significant difference between the
two groups (by independent t-test for continuous variables and by w2-test for
categorical variables).
The values are expressed as means, standard deviations, and percentages.
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3 of the 15 AR patients, who all had values 475 pg/ml
(Figure 1). The mean anti-PKCz level in these three patients
was 109±34.4 pg/ml. This was significantly greater than the
mean anti-PKCz level in the remaining 12 patients,
31.1±3.1 pg/ml (Po0.001). Comparative HLA and biopsy
information for the patients with high anti-PKCz levels and
low anti-PKCz levels is shown in Table 2. There was no
association between the presence of high anti-PKCz levels
and the pathological severity of rejection, as graded by the
Banff criteria (P¼ 0.63), or a diagnosis concurrent to
antibody-mediated rejection (P¼ 0.24). In addition, there
was no correlation between high anti-PKCz levels and the
presence of dense CD20-positive cell clusters (P¼ 0.44).
Finally, there was no association between high anti-PKCz
titers and development of antibodies to HLA targets. This
held true both for DSA (P¼ 0.60) and non-DSA HLA
antibodies (P¼ 0.44).
Allograft survival analysis
When the high anti-PKCz and the low anti-PKCz patients
were assessed by Kaplan–Meier analysis (Figure 2), at a mean
follow-up of 4.5±0.5 years, the low anti-PKCz patients had
significantly better allograft survival than the patients with
high anti-PKCz levels (100% versus 33%; P¼ 0.002).
Although 4 of the 15 AR patients had C4d staining evident
in their AR biopsy, none of the three patients with high anti-
PKCz levels had positive C4d staining.
Immunohistochemical staining for PKCf
To evaluate the localization of the PKCz antigen in the
transplant and the native kidney, immunohistochemical
(IHC) staining was performed. PKCz was shown in native
and transplanted, non-rejecting kidney tissue, localizing both
to the smooth muscle layer of arterioles and to the
cytoplasmic domain of distal tubular cells (Figure 3a
and b). IHC staining of renal allografts during AR shows
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Figure 1 | Enzyme-linked immunosorbent assay (ELISA)
analysis of 15 patients with acute rejection (AR) and 28 stable
posttransplant patients. Among the three groups (pre-
transplant, posttransplant with AR, and posttransplant stable)
there was a non-significant trend toward higher at-event anti-
protein kinase C-z (anti-PKCz) levels (P¼ 0.07). The three patients
with high anti-PKCz levels had a mean concentration of
109±34.4 pg/ml. This was more than three times the mean
concentration of the remaining 12 patients, that is, 31.1±3.1 pg/ml.
This difference was statistically significant (Po0.001). The long
horizontal bars represent the mean value for each group and the
short horizontal bars represent one standard deviation. None of
the patients had high anti-PKCz levels pre-transplant (mean value
30.9±5.1 pg/ml). This suggests that the anti-PKCz response in the
three patients is de novo.
Table 2 |HLA antibody and biopsy data for patients with high
and low anti-PKCf levels
Characteristic
Patients
with high
anti-PKCf
titers
Patients
with low
anti-PKCf
titers P-value
Number of patients 3 12
Allograft survival 33.3% 100% 0.002
Biopsy Banff score 0.63
1a 1 3
1b 2 6
2a 0 3
Antibody-mediated rejection 0% 33% 0.24
Dense CD20-positive clusters 33.3% 58.3% 0.44
Presence of donor-specific antibody
at AR
66.7% 50% 0.60
Presence of non-donor-specific
antibody HLA antibodies at AR
66.7% 41.7% 0.44
Presence of any HLA antibody at AR 100% 75% 0.33
AR, acute rejection; HLA, human leukocyte antigen; PKCz, protein kinase C-z.
Association of HLA antibody and biopsy factors with anti-PKCz levels. P-values
o0.05 represent a significant association between high anti-PKCz and the
respective variable.
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Figure 2 |Kaplan–Meier analysis of two subtypes of acute
rejection (AR) based on serum anti-protein kinase C-z
(anti-PKCz) levels. The gray line represents the 12 patients with
low serum anti-PKCz levels and the black line represents the
3 patients with high serum anti-PKCz levels. Allograft survival for
patients with high anti-PKCz levels was lower (33%) than that for
patients with low anti-PKCz levels (100%). This was significantly
different (P¼ 0.002).
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the presence of PKCz additionally in lymphocytes, both
within lymphocyte aggregates and scattered throughout the
tubulointerstitium (Figure 3c and d).
DISCUSSION
These results show the feasibility of applying protein
microarrays to renal transplant recipients. It is a novel and
emerging technology with the capacity to identify thousands
of potential immunogenic non-HLA antigens. Previously,
Robinson et al.14 fabricated an 1152-feature protein micro-
array that was used to show specific autoantibody binding
and characterize sera in known autoimmune disease states.
The currently used ProtoArray platform from Invitrogen
offers a human protein microarray containing 5056 antigens.
To date, there is a single publication using this technology to
study human disease. In this study, the ProtoArray was
probed with sera from patients with ovarian cancer.13
Although no target was identified universally in patients
with ovarian cancer, autoantibodies to four antigens were
found to have higher reactivity in patients with ovarian
cancer when compared with healthy controls. Although not
all patients with ovarian cancer formed detectable auto-
antibodies to these targets, combined immunostaining for
two of the targets identified by protein microarray led to a
highly sensitive and specific tissue diagnosis tool.
We have used the ProtoArray for the first time in solid
organ transplantation to determine whether de novo, non-
HLA targets, with clinical and prognostic relevance, can be
identified in transplant patients experiencing AR. With this
technology, we found biologically relevant antibody targets in
multiple patients at AR. Interestingly, the repertoire of
antigens recognized seems to be patient specific, with variable
reactivity to the range of protein targets; the patients had
antibody responses to between 0.1% and 4.1% of the possible
antigens. In addition, in our small cohort, the number and
specificity of antigen targets recognized did not seem to be
associated with the development of HLA antibodies. In total,
36 of the 5056 antigens were recognized in at least 2 of the 15
AR patients. This seemingly low number is not surprising
given that the ProtoArray was not designed to examine renal-
related antigens or transplant-specific targets. It is likely that
a protein microarray optimized for solid organ transplanta-
tion would have a higher net yield. Despite this, we were able
to identify antibodies to numerous biologically relevant
antigen targets, simultaneously using a single test and
minimal patient serum. Given the preliminary nature of this
study, we chose one such relevant target, PKCz, for additional
analysis. PKCz was chosen because it had the strongest mean
signal intensity of the 36 potential antigens, it is known to be
present in renal tissue, and it is involved in inflammatory
signal transduction pathways. Comprehensive analysis of
other relevant targets will be the focus of future investigation.
Protein Kinase C-z, which is expressed in a number of
tissues, including brain, kidney, lung, and testes,25 is an
atypical PKC which is an integral component of several
pathways involved in cell survival, proliferation, and
apoptosis17,20,21 Animal model data are concordant with
available in vitro data, suggesting that PKCz has an active,
regulatory role in inflammation. PKCz-deficient mice
(PKCz) have reduced Peyer’s patch formation, a relative
reduction of B cells in peripheral lymph nodes, and no B-cell
follicle formation.16 In addition, they lack the anti-apoptotic
signal mediated by tumor necrosis factor-a-activated NF-kB,
which is present in normal mice. In a renal ischemia/reper-
fusion rat model, PKCz had significantly upregulated expres-
sion during the first hour of reperfusion, at 1 day after
reperfusion, and at days 5–7 after reperfusion.19 Human
studies have been consistent with the in vitro and animal
model data, establishing the active role PKCz has in inflam-
matory cell signaling and cell survival. PKCz is involved in
intracellular signaling in human monocytes and macro-
phages, and mediates lipopolysaccharide-activated pro-in-
flammatory cytokine gene expression.23 In addition, PKCz
mediates regulation of the mitogen-activated protein kinase
and mammalian target of rapamycin pathways in follicular
lymphoma cells, and seems to exert a survival function in
these cells. Administration of rituximab, a humanized anti-
CD20 immunotherapy, led to reduced PKCz activity and
inhibited its survival effects.18 Finally, Zhao et al.22 recently
showed increased PKCz expression in psoriatic skin lesions
compared with healthy skin. tumor necrosis factor-a, a well-
described pathogenic factor in psoriasis, was found to be
dependent on PKCz for cell signaling and signal transduc-
tion. After tumor necrosis factor-a stimulation, cytoplasmic
and nuclear staining for PKCz was increased. Furthermore,
Figure 3 | Immunohistochemical staining for PKCf in normal
renal tissue and renal parenchyma experiencing acute rejection.
Within normal kidney (a and b), cytoplasmic granular staining for
PKCz is observed in a subset of tubules morphologically
compatible with distal tubules (b) and the smooth muscle cells
of the arteries (a). Patchy endothelial cell staining is observed in
a few capillaries. No significant staining is observed in glomeruli
except for an occasional infiltrating lymphocyte. In acute rejection
(c and d), the tubular staining is less intense, but the infiltrating
lymphocytes are PCKz-positive, both when scattered (d) and
when arranged in aggregates (c). Negative controls were run to
identify non-specific anti-PKCz staining. Tissue from non-rejecting
allografts had a similar staining pattern to those of normal kidney
(data not shown).
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activation of PKCz was associated with an increased
expression of CD1d, which interacts with natural killer T
cells, and has an integral role in their cytokine production.
Thus, PKCz seems to have a significant role in inflammatory
cell signaling and may be upregulated in inflammatory
disease states, such as acute allograft rejection.
In our analysis, although there was a slight trend toward
higher anti-PKCz levels in the at-AR cohort compared with
the pre-transplant and stable posttransplant cohorts, this
trend failed to reach statistical significance. However, a subset
of patients within the AR cohort had robust anti-PKCz
responses, suggesting the presence of an AR subtype. When
allograft survival was assessed, the patients with elevated anti-
PKCz levels had significantly worse outcomes and anti-PKCz
levels were significantly associated with accelerated allograft
loss at mean follow-up of 4.5±0.5 years.
It is important to interpret these results with caution;
given the small size of our cohort, we cannot rule out that
anti-PKCz levels are elevated merely because of increased
expression, abnormal splicing or protein folding, or poly-
morphism. In addition, although high anti-PKCz titers were
significantly associated with allograft loss in our study, there
is no evidence of causality. In fact, given that none of the
three patients with high anti-PKCz titers had evidence of C4d
deposition in their AR biopsies, it is likely that anti-PKCz is a
marker, or bystander molecule, related to cellular damage
associated with severe AR, rather than being truly patho-
genic. The fact that higher anti-PKCz levels were not
associated with development of HLA antibodies would also
suggest a different mechanism than that seen with DSAs in
antibody-mediated rejection. Our IHC results show that
PKCz is indeed present in renal parenchymal cells, localizing
to smooth muscle and distal tubular cells in healthy renal
allograft tissue. The presence of PKCz within renal tubular
cells is consistent with a recent study which showed that
PKCz is present in and regulates organic anion transporters
in renal proximal tubular cells.26 Interestingly, in the
setting of AR, our IHC staining also found PKCz within
infiltrating lymphocytes, suggesting either upregulation
within the inflammatory cell or immunological exposure to
the intracellular antigen. Our results are consistent with the
premise that PKCz is upregulated in the inflammation
associated with AR; we hypothesize that in our subset of
AR patients with high anti-PKCz levels, severe renal injury
and cell death led to immunological exposure of PKCz with
resultant antibody formation. In this setting, the elevated
anti-PKCz titer may be a marker for the damage associated
with a more severe subtype of AR. Interestingly, in our small
pilot study, there did not seem to be a specific histological
feature that was associated with AR and the presence of
higher anti-PKCz levels; however, it is possible that in a larger
patient cohort such a characteristic might be found.
In summary, protein microarrays were able to successfully
identify AR-specific antigenic targets in a high throughput
manner and represent an appealing technology to better
assess alloimmunity in solid organ transplantation. In
addition, based on our results, PKCz is a potential non-
HLA antigen target recognized in pediatric renal transplant
patients experiencing AR. It is not a target in all AR episodes,
but there seems to be a subtype of AR, characterized by expo-
sure of and antibody formation against PKCz, which is asso-
ciated with poor allograft survival. Our results suggest that
anti-PKCz is a marker, rather than a truly pathogenic anti-
body and further research is necessary to accurately define
the role that PKCz has in AR.
METHODS
Patient selection
A review of our pediatric transplant database identified patients who
had undergone renal allograft transplantation and experienced at
least one episode of acute allograft rejection. A total of 15 patients
were selected based on availability of serum samples, both before
transplantation and at the time of AR. All transplant allograft
biopsies were graded on the basis of the Banff classification.27,28 Pre-
transplant serum samples were obtained within 48 h before allograft
placement. The at-AR serum samples were obtained concurrently
with the biopsy showing AR and before initiation of anti-rejection
therapy. No patients received antibody therapy, including intrave-
nous immunoglobulin, before the sample being obtained. Anti-HLA
testing was performed as standard posttransplant care and the
results were obtained from our histocompatibility laboratory. Pre-
and posttransplant serum samples from all 15 AR patients were
processed for ProtoArray and ELISA experiments. An additional 28
stable, posttransplant pediatric renal allograft recipients were
selected as controls for the ELISA analysis using our validated
PKCz ELISA. These 28 patients were chosen based on clinical
similarity to the 15 AR patients and the presence of a posttransplant
surveillance biopsy showing the absence of AR. Serum samples for
these patients were obtained concurrently with the biopsy showing
the absence of AR. Pre-transplant serum samples were not available
for these 28 allograft recipients. These serum samples were processed
for ELISA experiments. All serum samples were available under a
previously institutional review board approved protocol (no 13443).
Identification of autoantibody targets using protein
microarray
A total of 30 protein microarrays (ProtoArray V3; Invitrogen,
Carlsbad, CA, USA) were used for this study, one each for the
pre-transplant and the at-AR serum samples of the 15 patients with
AR. The ProtoArrays were blocked with blocking buffer for 1 h
followed by application of plasma sample (1:150) for 90min. After
washing the protein microarray four times for 10min each, the
protein microarrays were probed with secondary antibody (goat
anti-human Alexa 647, Molecular Probes, Eugene, OR, USA) for
90min. After washing the slides, the protein microarrays were dried
and scanned using a fluorescent microarray scanner (GSI Lumi-
noics, Perkin-Elmer scanner, Waltham, MA, USA). All steps were
carried out on a rotating platform and at 41C. The slides were
scanned at a photomultiplier gain of 60% with a laser power of 90%
and a focus point of 0 mm. The ‘.gal’ files were obtained from a
ProtoArray central portal on the Invitrogen website (www.invitrogen.
com/ProtoArray) by submitting the barcode of each protein
microarray. Data was obtained using GenePix software (Version 6,
Molecular Devices, Sunnyvale, CA, USA). Using the appropriate ‘.gal’
file and the respective microarray image obtained from the scanners.
Novel alloimmune antibody responses are identified by subtracting
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the pre-transplant data set from the posttransplant data set (delta);
all reported ProtoArray signal intensities represent the delta
intensity (signal at ARsignal pre-transplant). A target response
was considered positive, and indicative of de novo antibody for-
mation, if the response delta, defined as the response intensity at AR
subtracting the pre-transplant response intensity, was arbitrarily 500
or greater. Positive antibody responses were arranged according to
occurrence frequency, and all targets identified in at least two pati-
ents were reviewed with specific attention directed at the strength of
the antibody response, human tissue expression data, gene ontology
of the target, and the relevance to immunological function. Given
the preliminary nature of this study, a single target, PKCz, was selec-
ted as a candidate target for further analysis on the basis of the
aforementioned factors.
ELISA validation of PKCf protein microarray results
Both the pre-transplant and the at-AR serum samples from
the 15 AR patients and the posttransplant serum samples
from the 28 stable kidney transplant recipients were analyzed
by ELISA. Insect cell-expressed human recombinant protein,
PKCz was obtained from Invitrogen. The 96-well microwell
ELISA plate was coated with 0.27 mg PKCz protein in 50 ml
coating buffer (15mM Na2CO3, 30mM NaHCO3, 0.02%
NaN3, pH 9.6) and incubating overnight at 41C. The stan-
dard curve was generated using rabbit polyclonal antibody to
PKCz (Abcam, Cambridge, MA, USA), and Zymax-grade AP-
conjugated goat anti-rabbit IgG (Invitrogen). After washing
the plate with tris-buffered saline tween 20 buffer five times,
the non-specific protein binding was blocked by 100 ml, 2%
dry milk in tris-buffered saline tween 20 buffer for 1 h at
room temperature. After the blocking step, 50 ml serum
samples (40-fold diluted with 2% milk in tris-buffered saline
tween 20 buffer) were incubated on the wells for 1 h at room
temperature. The plate was washed five times with tris-
buffered saline tween 20 buffer and incubated in 50 ml AP-
conjugated AffiniPure Mouse anti-human IgG (Jackson
ImmunoResearch, West Grove, PA, USA). The color was
developed by using AP-pNPP liquid substrate system for
ELISA (Sigma-Aldrich, St Louis, MO, USA). Absorption was
measured at 405 nm with a SPECTRAMax 190 microplate
reader (Molecular Devices, Sunnyvale, CA, USA). Serum
PKCz antibody concentrations were determined from the
standard curve.
Longitudinal allograft survival analysis
Allograft survival was assessed in the 15 patients with AR in
the study set. Patients were divided into AR subtypes based
on their serum anti-PKCz levels at AR: 3 with high serum
anti-PKCz levels and 12 with low serum anti-PKCz levels.
Follow-up commenced at the time of the initial AR event.
Follow-up was continued until allograft loss occurred or until
the time of most recent assessment of allograft function.
Allograft loss was defined as a return to dialysis.
IHC staining for PKCf in renal parenchyma
Immunohistochemical staining was performed using anti-
bodies directed against PKCz (GeneTex, San Antonio, TX,
USA catalog no GTX40214). Formalin-fixed, paraffin-
embedded tissue were pretreated with citrate and stained
with polyclonal antiserum to PKCz (dilution 1:2000 for 18 h).
A rabbit ABC detection kit (Vector Labs, Burlingame, CA,
USA) was used (PK-6101). Negative controls were run to
assess for non-specific anti-PKCz staining.
Statistical analysis
t-Test, ANOVA (analysis of variance), and w2-test were used
for analysis of continuous or categorical types of data.
Correlation analysis was performed for antigens detected by
ProtoArray and ELISA. Graft survival rate was based on
Kaplan–Meier survival analysis at current follow-up. P-values
p0.05 were considered statistically significant. Results are
reported as mean±standard deviation. All statistical analyses
were performed using SAS 9.1.3 (SAS Institute, Cary, NC,
USA).
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